相关临床试验
7
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
28.6%
已完成
3
42.9%
尚未招募
2
28.6%
暂无批准数据
- In the LATA trial, 1 per cent of adolescents on eight-weekly cabotegravir and rilpivirine injections had confirmed viral rebound at 96 weeks versus 6 per cent on daily tablets. - The trial randomised 476 adolescents aged 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe, all previously suppressed on oral antiretrovirals. - Ninety-four per cent of participants in the injectable arm said treatment every eight weeks was much easier than taking daily medicines. - Researchers called for wider access in low- and middle-income settings, where long-acting injectables remain unavailable outside a small number of clinics.
- A Frankfurt Airport employee has died of malaria, with five additional employees infected and receiving medical treatment, according to airport operator Fraport. - The infections are attributed to a single mosquito believed to have traveled by plane from a malaria-endemic area to Germany, likely in July. - The Robert Koch Institute and Frankfurt Health Department describe "airport malaria" as a very rare transmission route, with human-to-human transmission playing no role. - A study of European airport and baggage-borne malaria from 1969 to 2024 identified 145 total cases, nine of which occurred in Germany.
- Sickle cell disease affects 4–6 million Nigerians, with recurrent vaso-occlusive crises driving heavy reliance on NSAIDs and opioids like pentazocine, tramadol, and morphine. - Healthcare professionals report rising opioid addiction among SCD patients, with studies in North-West Nigeria finding an 11.7% opioid use disorder prevalence. - Experts warn that indiscriminate NSAID use can cause peptic ulcers and kidney injury, while opioid misuse leads to dependence, injection-site infections, and blood-borne diseases. - Pharmacists and clinicians call for coordinated efforts including prescription monitoring, patient education, and evidence-based pain management protocols to prevent addiction.
- Lucis raised $20 million in Series A funding led by Singular, bringing total funding to $28 million just four months after an $8 million seed round. - The AI-powered platform analyzes over 110 blood biomarkers and has demonstrated that 75% of users improved at least three biomarkers without medication after six months. - The company plans to expand into Spain, Germany, and Italy by 2026, targeting Europe's preventive healthcare market where 1.8 million deaths annually could be prevented through early intervention. - Lucis currently serves over 10,000 users across France, UK, Ireland, and Portugal, with 99.9% of initial users showing at least one biomarker outside optimal ranges.
- Kenya has announced a partnership with the Africa Medicines Agency to fast-track pharmaceutical product registration and reduce delays in accessing essential medicines. - The collaboration aims to harmonize pharmaceutical documentation with continental standards while strengthening Kenya's regulatory capacity for health product approval. - Kenya is pursuing WHO Maturity Level 3 status for health product regulation to enhance access to quality medicines and support local pharmaceutical manufacturing. - The initiative includes upgrading the National Quality Control Laboratory with plans to repair six HPLC machines and reduce turnaround times to 42 days.
- Two new clinical trials involving 95 participants demonstrate that replacing bread with specific Indian mango varieties produces similar or lower glycemic responses in type 2 diabetes patients. - A week-long study of 35 adults with type 2 diabetes found that substituting 250g of mango for bread improved insulin resistance, fasting glucose, weight, and waist circumference. - The research challenges conventional dietary wisdom that mangoes should be avoided by diabetics, showing that moderate consumption within prescribed diets may be beneficial for blood glucose management. - Researchers emphasize that moderation and clinical supervision remain essential, with mango calories counting toward daily caloric limits rather than as additional intake.
- India's Subject Expert Committee has recommended upgrading Biological E's Corbevax COVID-19 vaccine from emergency use authorization to full drug approval for individuals aged 5 years and above after reviewing extensive safety and efficacy data. - The indigenous RBD protein sub-unit vaccine has demonstrated persistent humoral response with binding antibody titers against the RBD protein and neutralizing antibody titers against SARS-CoV-2 for up to one year post-vaccination. - With over 85 million doses administered globally and WHO Emergency Use Listing achieved in January 2024, Corbevax has shown no additional safety concerns throughout its widespread implementation in vaccination programs.
• Indigenously developed HPV test kits for cervical cancer screening were launched in Delhi, targeting the seven to eight most common cancer-causing HPV types specific to India's population. • The RTPCR-based diagnostic kits, validated through collaborative research led by AIIMS Delhi, offer a cost-effective alternative to traditional Pap smears and HPV DNA tests for national cancer screening programs. • With cervical cancer being the second most common cancer among Indian women and accounting for 25% of global mortality, these kits align with WHO's recommendation for HPV testing as the preferred screening method.
• Lenacapavir, a twice-yearly HIV prevention drug, is being fast-tracked for registration in South Africa, potentially revolutionizing the fight against new infections. • Clinical trials have demonstrated lenacapavir's high effectiveness, with up to 100% protection against HIV in certain groups, marking it as a promising preventative measure. • South African regulatory authorities are expediting the approval process, leveraging international programs to reduce review times from years to months. • The drug's long-acting formulation enhances adherence to treatment, but its cost-effectiveness is under review to ensure affordability for the South African healthcare system.
- The European Medicines Agency's advisory committee issued a positive opinion on lenacapavir for pre-exposure prophylaxis, marking the final regulatory hurdle before formal approval by the European Commission. - Lenacapavir demonstrated 100% efficacy in preventing HIV transmission during clinical trials, offering a twice-yearly injection alternative to daily prevention pills. - The approval comes as HIV cases rose 11.8% in Europe in 2023, with over 24,700 new diagnoses across the EU, Iceland, Liechtenstein, and Norway. - Gilead Sciences has committed to making generic versions available in 120 low-income countries, though concerns remain about equitable global access.
